Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066

Watchlist Manager
Shandong Weigao Group Medical Polymer Co Ltd Logo
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
Watchlist
Price: 4.34 HKD 2.84% Market Closed
Market Cap: 19.8B HKD
Have any thoughts about
Shandong Weigao Group Medical Polymer Co Ltd?
Write Note

Gross Margin
Shandong Weigao Group Medical Polymer Co Ltd

49.9%
Current
53%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
49.9%
=
Gross Profit
6.5B
/
Revenue
13B

Gross Margin Across Competitors

Country CN
Market Cap 19.8B HKD
Gross Margin
50%
Country JP
Market Cap 7T JPY
Gross Margin
86%
Country CH
Market Cap 37.9B CHF
Gross Margin
55%
Country DK
Market Cap 178.7B DKK
Gross Margin
68%
Country US
Market Cap 16.1B USD
Gross Margin
70%
Country KR
Market Cap 10.3T KRW
Gross Margin
15%
Country CN
Market Cap 49B CNY
Gross Margin
72%
Country US
Market Cap 6.5B USD
Gross Margin
65%
Country CA
Market Cap 6.4B USD
Gross Margin
61%
Country US
Market Cap 5.7B USD
Gross Margin
47%
Country UK
Market Cap 4.6B GBP
Gross Margin
56%
No Stocks Found

Shandong Weigao Group Medical Polymer Co Ltd
Glance View

Market Cap
19.8B HKD
Industry
Health Care

Nestled in the bustling industrial heart of China, Shandong Weigao Group Medical Polymer Co Ltd stands as a testament to the transformative potential within the field of medical devices. Since its inception in 1988, Weigao has diligently carved out a niche within the healthcare sector, specializing in the production and distribution of medical consumables, orthopedic materials, and blood purification apparatus. The company's journey is intertwined with China's healthcare evolution, as it became a critical player in supplying hospitals and medical institutions with essential, reliable tools. By leveraging advancements in polymer science, Weigao consistently pushes the boundaries in creating high-quality, cost-effective products—a maneuver that not only reduces healthcare costs but also ensures widespread accessibility to essential medical supplies. Driven by an intricate understanding of the medical landscape, Weigao's operational model hinges on its robust vertical integration strategy. The company effectively controls every stage of its production process, from raw material procurement to product manufacturing and distribution. This control not only ensures stringent quality checks but also allows for improved economies of scale, thereby boosting its profitability margins. Revenue streams largely stem from its extensive product lineup, which includes syringes, blood bags, infusion sets, and orthopedic devices, catering to domestic demand while also penetrating international markets. The constant stream of innovations, coupled with an expanding global footprint, underscores Weigao's commitment to growth, firmly positioning it as a stalwart in the medical apparatus industry.

Intrinsic Value
8.37 HKD
Undervaluation 48%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
49.9%
=
Gross Profit
6.5B
/
Revenue
13B
What is the Gross Margin of Shandong Weigao Group Medical Polymer Co Ltd?

Based on Shandong Weigao Group Medical Polymer Co Ltd's most recent financial statements, the company has Gross Margin of 49.9%.